Paraoxonase and arylesterase activities in the serum of two hyperlipoproteinaemic patients after repeated extracorporal lipid precipitation.
The effect of heparin-induced extracorporal lipid precipitation (HELP) on the activities of paraoxonase (EC 3.1.8.1) and arylesterase (EC 3.1.1.2) was studied in serum of a patient with hyperlipoproteinaemia (A) and of a patient with non-insulin dependent diabetes mellitus and hyperlipoproteinaemia (B). The enzyme activities were measured spectrophotometrically (Tris-HCl buffer, pH 7.4, 37 degrees C) with paraoxon and phenylacetate as substrates of paraoxonase and arylesterase, respectively. Both patients underwent HELP applications once a week over a period of 7 weeks. Over that period no overall change was observed either in enzyme activities or in the lipid and protein content of the sera. However, each HELP session caused an immediate decrease of EDTA-insensitive arylesterase activity (on average 56% in A and 42% in B), while EDTA-sensitive arylesterase remained almost unaltered. Paraoxonase remained unchanged in A, but decreased in B (approximately 60%). Of the atherogenic lipoprotein parameters, the most pronounced decrease was found in VLDL-cholesterol and in triglycerides (on average 45% in A and 32% in B), while the anti-atherogenic HDL-cholesterol decreased < 10%. Possible implications of the effect of HELP on the enzyme activities studied remain to be explained.
Reiner
E
E
Institute for Medical Research and Occupational Health, Zagreb, Croatia.
Svedruzic
D
D
Simeon-Rudolf
V
V
Lipovac
V
V
Gavella
M
M
Mrzljak
V
V
D043303:Aryldialkylphosphatase; D002265:Carboxylic Ester Hydrolases / Q000097:blood*; D002614:Chelating Agents / Q000494:pharmacology; D011232:Chemical Precipitation; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000201:enzymology; D004492:Edetic Acid / Q000494:pharmacology; D004950:Esterases / Q000097:blood*; D005112:Extracorporeal Circulation / Q000379:methods; D006493:Heparin; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000150:complications / Q000201:enzymology* / Q000628:therapy*; D008055:Lipids / Q000097:blood*; D010261:Paraoxon / Q000378:metabolism; D010648:Phenylacetates / Q000378:metabolism; D006435:Renal Dialysis; D013379:Substrate Specificity
D002614:Chelating Agents; D008055:Lipids; D010648:Phenylacetates; D006493:Heparin; D004492:Edetic Acid; D004950:Esterases; D002265:Carboxylic Ester Hydrolases; C019734:arylesterase; D043303:Aryldialkylphosphatase; C025136:phenylacetic acid; D010261:Paraoxon